Literature DB >> 30242450

Anti-cancer immunotherapy: breakthroughs and future strategies.

Mads Hald Andersen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30242450     DOI： 10.1007/s00281-018-0711-z

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN： 1863-2297            Impact factor:   9.623


× No keyword cloud information.
  12 in total

1.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

Review 2.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

Review 3.  Therapeutic cancer vaccine: building the future from lessons of the past.

Authors:  T Tran; C Blanc; C Granier; A Saldmann; C Tanchot; Eric Tartour
Journal:  Semin Immunopathol       Date:  2018-07-05       Impact factor: 9.623

Review 4.  Does patient age influence anti-cancer immunity?

Authors:  Graham Pawelec
Journal:  Semin Immunopathol       Date:  2018-07-13       Impact factor: 9.623

Review 5.  Cancer immune therapy for lymphoid malignancies: recent advances.

Authors:  Uffe Klausen; Nicolai Grønne Dahlager Jørgensen; Jacob Handlos Grauslund; Morten Orebo Holmström; Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2018-07-13       Impact factor: 9.623

Review 6.  Principles of adoptive T cell therapy in cancer.

Authors:  Özcan Met; Kasper Mølgaard Jensen; Christopher Aled Chamberlain; Marco Donia; Inge Marie Svane
Journal:  Semin Immunopathol       Date:  2018-09-05       Impact factor: 9.623

Review 7.  Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.

Authors:  Michelle L Saetersmoen; Quirin Hammer; Bahram Valamehr; Dan S Kaufman; Karl-Johan Malmberg
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

Review 8.  Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.

Authors:  Alexander J Muller; Mark G Manfredi; Yousef Zakharia; George C Prendergast
Journal:  Semin Immunopathol       Date:  2018-09-10       Impact factor: 9.623

Review 9.  Acquired resistance to cancer immunotherapy.

Authors:  Arianna Draghi; Christopher Aled Chamberlain; Andrew Furness; Marco Donia
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

Review 10.  The T-win® technology: immune-modulating vaccines.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623
View more
  3 in total

Review 1.  Current Perspectives in Cancer Immunotherapy.

Authors:  Theodoulakis Christofi; Stavroula Baritaki; Luca Falzone; Massimo Libra; Apostolos Zaravinos
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

2.  Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.

Authors:  Mingxia Jiang; Liping Zhao; Xiaoming Cui; Xinghan Wu; Yuhan Zhang; Xiuwen Guan; Jinlong Ma; Weifen Zhang
Journal:  J Adv Res       Date:  2021-08-19       Impact factor: 10.479

3.  A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

Authors:  Julie Westerlin Kjeldsen; Cathrine Lund Lorentzen; Evelina Martinenaite; Eva Ellebaek; Marco Donia; Rikke Boedker Holmstroem; Tobias Wirenfeldt Klausen; Cecilie Oelvang Madsen; Shamaila Munir Ahmed; Stine Emilie Weis-Banke; Morten Orebo Holmström; Helle Westergren Hendel; Eva Ehrnrooth; Mai-Britt Zocca; Ayako Wakatsuki Pedersen; Mads Hald Andersen; Inge Marie Svane
Journal:  Nat Med       Date:  2021-12-09       Impact factor: 53.440
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.